News

The trial results indicated 3 significant improvements across all AHFD subtypes with dupilumab treatment compared to placebo.

Catch up on coverage from the first day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.

Improvements persisted through the 12-week post-treatment follow-up, indicating sustained efficacy even after discontinuation of dupilumab.

Four leaders in HS treatment and care put a spotlight on the latest clinical trial data and treatment techniques.

Terry Arnold, PA-C, shared his journey and advice for PAs and NPs looking to transition out of a clinical practice.

Significant improvements were observed in EASI scores across all anatomical regions, regardless of patient age or specific body region.

Earlier this week, we shared our fourth and final Skin Cancer Awareness Month quiz. Review the answers and your responses below.

Dermatology Times is looking back on the top stories in dermatology from the month of May.

Dermatology Times will bring clinical insights from leading experts in numerous dermatology specialties.

Novartis announced late-breaking data for the BTK inhibitor at the 2024 European Academy of Allergy and Clinical Immunology Congress.

Raj Chovatiya, MD, PhD, reviews the varying degrees of influence of skin barrier disruption, immune dysregulation, and Malassezia yeast in seborrheic dermatitis.

The phase 2 study achieved the primary end point of a >30% Severity of Alopecia Tool score improvement.

Dermatology Times is recapping our top expert interviews from the month of May.

May is Asian American and Pacific Islander Heritage Month. We review articles from the past month spotlighting dermatologic concerns in this patient population.

Chovatiya was a lead author of the latest seborrheic dermatitis and roflumilast foam review published in the Journal of Clinical and Aesthetic Dermatology.

Learn more about the in-depth topics covered in the May 2024 supplement of Dermatology Times.

The treatment is the first IL-17 targeting topical therapy being developed for less severe cases of psoriasis.

Learn more about the in-depth topics covered in the May 2024 print issue of Dermatology Times.

The study is the first to be approved by the European Medicines Agency to perform human clinical trials with a novel therapeutic mAb.

Miranti previews her sessions from the meeting which kicks off tomorrow, May 30, in Orlando, Florida.

This research indicates that psychological well-being serves a key role in the management of psoriatic disease.

The study not only showed success for patients with severe psoriasis, but also suggested it may be worth trying before other biologics.

Whether you are attending in-person or looking to Dermatology Times coverage, let us know which topics interest you most.

Hadar Lev-Tov, MD, MAS, President of the HS Foundation, discusses the organization's hopes for the future and upcoming efforts.

Supportive data for roflumilast in adults and children 6 years of age and older stems from the INTEGUMENT studies.

Based on these findings, Innovent plans to submit a New Drug Application to the Center for Drug Evaluation of National Medical Product Administration.

Social media is fraught with misinformation. Pharmacists play a key role in breaking through the fallacies with facts and education on skin care.

The month of May has been full of pipeline news, including updates on VYN201 for nonsegmental vitiligo, imsidolimab for GPP, sonelokimab for HS, and more.

Click here to read more and answer our quiz questions in recognition of Skin Cancer Awareness Month.

Keep up with the latest headlines in dermatology from the past week, including exposure to UV light and its implications for metabolism, the effects of skin conditions on children, and more.